Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 5432818, 8 pages
https://doi.org/10.1155/2017/5432818
Research Article

Role of ARPC2 in Human Gastric Cancer

1Department of General Surgery, Third Affiliated Hospital (Hefei First People’s Hospital) of Anhui Medical University, Hefei, China
2Department of Gastrointestinal Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China

Correspondence should be addressed to Yi Liu; moc.621@dravrah02uily

Received 4 December 2016; Accepted 6 March 2017; Published 13 June 2017

Academic Editor: Yingqiu Xie

Copyright © 2017 Jun Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. D. H. Wang, Z. S. Fan, F. L. Liu, and J. Zuo, “Hsa-miR-21 and Hsa-miR-29 in tissue as potential diagnostic and prognostic biomarkers for gastric cancer,” Cellular Physiology and Biochemistry, vol. 37, pp. 1454–1462, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. S. H. Wu, F. Liu, L. M. Xie et al., “miR-125b suppresses proliferation and invasion by targeting MCL1 in gastric cancer,” BioMed Research International, vol. 2015, Article ID 365273, p. 10, 2015. View at Google Scholar
  4. C. Yan, J. C. Yu, Y. Q. Liu, W. M. Kang, Z. Q. Ma, and L. Zhou, “MiR-32 promotes gastric carcinoma tumorigenesis by targeting Kruppel-like factor 4,” Biochemical and Biophysical Research Communications, vol. 467, pp. 913–920, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. H. L. Tang, Y. N. Kong, J. L. Guo et al., “Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22,” Cancer Letters, vol. 340, pp. 72–81, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Al Ghouleh, A. Rodriguez, P. J. Pagano, and G. Csanyi, “Diallyl disulfide suppresses proliferation and induces apoptosis in human gastric cancer through Wnt-1 signaling pathway by up-regulation of miR-200b and miR-22,” International Journal of Molecular Sciences, vol. 14, pp. 20220–20235, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. K. M. Daugherty and B. L. Goode, “Functional surfaces on the p35/ARPC2 subunit of Arp2/3 complex required for cell growth, actin nucleation, and endocytosis,” Journal of Biological Chemistry, vol. 283, pp. 16950–16959, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. L. M. Machesky, S. J. Atkinson, C. Ampe, J. Vandekerckhove, and T. D. Pollard, “Purification of a cortical complex containing two unconventional actins from Acanthamoeba by affinity chromatography on profilin-agarose,” The Journal of Cell Biology, vol. 127, pp. 107–115, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. M. D. Welch, A. H. DePace, S. Verma, A. Iwamatsu, and T. J. Mitchison, “The human Arp2/3 complex is composed of evolutionarily conserved subunits and is localized to cellular regions of dynamic actin filament assembly,” The Journal of Cell Biology, vol. 138, pp. 375–384, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Gournier, E. D. Goley, H. Niederstrasser, T. Trinh, and M. D. Welch, “Reconstitution of human Arp2/3 complex reveals critical roles of individual subunits in complex structure and activity,” Molecular Cell, vol. 8, pp. 1041–1052, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Havelkova, G. Nanda, J. Martinek et al., “Arp2/3 complex subunit ARPC2 binds to microtubules,” Plant Science: An International Journal of Experimental Plant Biology, vol. 241, pp. 96–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Melboucy-Belkhir, P. Pradere, S. Tadbiri et al., “Forkhead box F1 represses cell growth and inhibits COL1 and ARPC2 expression in lung fibroblasts in vitro,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 307, pp. L838–L847, 2014. View at Google Scholar
  13. J. Kang, J. K. Perry, V. Pandey et al., “Artemin is oncogenic for human mammary carcinoma cells,” Oncogene, vol. 28, pp. 2034–2045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Tan, K. S. Ding, R. Li et al., “Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2,” Breast Cancer Research, vol. 16, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Y. Ding, G. N. Jin, W. Wang et al., “Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma,” Hepatology, vol. 60, pp. 1620–1636, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Giatromanolaki, E. Sivridis, A. Mitrakas et al., “Autophagy and lysosomal related protein expression patterns in human glioblastoma,” Cancer Biology & Therapy, vol. 15, pp. 1468–1478, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Namikawa, E. Munekage, M. Munekage et al., “Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer,” Molecular and Clinical Oncology, vol. 5, pp. 74–78, 2016. View at Publisher · View at Google Scholar
  18. J. H. Kang, S. I. Lee, D. H. Lim et al., “Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone,” Journal of Clinical Oncology, vol. 30, pp. 1513–1518, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Kurokawa, N. Matsuura, Y. Kimura et al., “Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer,” Gastric Cancer, vol. 18, pp. 691–697, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. H. I. Balcer, K. Daugherty-Clarke, and B. L. Goode, “The p40/ARPC1 subunit of Arp2/3 complex performs multiple essential roles in WASp-regulated actin nucleation,” The Journal of Biological Chemistry, vol. 285, pp. 8481–8491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Tang, F. Tang, Z. Wang et al., “Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinous characters through activation of Wnt/β-catenin signaling,” Journal of Experimental & Clinical Cancer Research, vol. 35, no. 1, p. 82, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. S. D. Castillo, B. Angulo, A. Suarez-Gauthier et al., “Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer,” The Journal of Pathology, vol. 222, pp. 89–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Wang, F. Gao, M. Zhao et al., “Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis,” Journal of Cellular and Molecular Medicine, vol. 20, pp. 836–841, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Zhang, J. Qi, J. M. Reyes et al., “Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer,” Cancer Discovery, vol. 6, no. 9, pp. 1006–1021, 2016. View at Publisher · View at Google Scholar
  25. S. Guo, X. Li, J. Rohr et al., “EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features,” Diagnostic Pathology, vol. 11, p. 41, 2016. View at Google Scholar
  26. S. Liu, D. Chen, W. Shen et al., “EZH2 mediates the regulation of S100A4 on E-cadherin expression and the proliferation, migration of gastric cancer cells,” Hepato-Gastroenterology, vol. 62, pp. 737–741, 2015. View at Google Scholar
  27. D. L. Chen, D. S. Zhang, Y. X. Lu et al., “microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer,” Oncotarget, vol. 6, pp. 10868–10879, 2015. View at Publisher · View at Google Scholar
  28. H. J. Chung, Y. E. Choi, E. S. Kim, Y. H. Han, M. J. Park, and I. H. Bae, “miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2,” Oncotarget, vol. 6, pp. 18429–18444, 2015. View at Publisher · View at Google Scholar
  29. T. Yang, A. Thakur, T. Chen et al., “MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, vol. 36, pp. 4357–4365, 2015. View at Google Scholar
  30. J. Qu, L. Zhao, P. Zhang et al., “MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA,” Journal of Cellular Physiology, vol. 230, pp. 535–545, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Ma, Y. Zhao, K. Wei et al., “MicroRNA-124 functions as a tumor suppressor by regulating CDH2 and epithelial-mesenchymal transition in non-small cell lung cancer,” Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, vol. 38, pp. 1563–1574, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Yanaka, T. Muramatsu, H. Uetake, K. Kozaki, and J. Inazawa, “miR-544a induces epithelial-mesenchymal transition through the activation of WNT signaling pathway in gastric cancer,” Carcinogenesis, vol. 36, pp. 1363–1371, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Huo, Z. Zheng, Y. Chen, Q. Wang, Z. Zhang, and H. Deng, “Downregulation of vimentin expression increased drug resistance in ovarian cancer cells,” Oncotarget, vol. 7, no. 29, pp. 45876–45888, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. D. L. Lazarova and M. Bordonaro, “Vimentin, colon cancer progression and resistance to butyrate and other HDACis,” Journal of Cellular and Molecular Medicine, vol. 20, pp. 989–993, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Li, Q. J. Wu, F. F. Bi et al., “Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer,” American Journal of Translational Research, vol. 8, pp. 1601–1608, 2016. View at Google Scholar
  36. X. Meng, B. Hu, M. M. Hossain, G. Chen, Y. Sun, and X. Zhang, “ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation,” International Journal of Oncology, vol. 49, pp. 682–690, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. C. C. Su and T. L. Chiu, “Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo,” Oncology Reports, vol. 36, pp. 1173–1179, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Xin, F. Bai, Y. Feng et al., “MicroRNA-214 promotes peritoneal metastasis through regulating PTEN negatively in gastric cancer,” Clinics and Research in Hepatology and Gastroenterology, vol. 40, no. 6, pp. 748–754, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. F. Pei, R. Tao, J. F. Li et al., “TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-expression,” Oncotarget, vol. 7, no. 21, pp. 31322–31335, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Golmohammadi, M. H. Rakhshani, A. R. Moslem, and A. Pejhan, “Prognostic role of PTEN gene expression and length of survival of breast cancer patients in the north east of Iran,” Asian Pacific Journal of Cancer Prevention: APJCP, vol. 17, no. S3, pp. 305–309, 2016. View at Google Scholar
  41. J. Gu, W. Ou, L. Huang et al., “PTEN expression is associated with the outcome of lung cancer: evidence from a meta-analysis,” Minerva Medica, vol. 107, no. 5, pp. 342–351, 2016. View at Google Scholar
  42. M. Matsumoto, W. Nakajima, M. Seike, A. Gemma, and N. Tanaka, “Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells,” Biochemical and Biophysical Research Communications, vol. 473, pp. 490–496, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Kubo, Y. Kawano, N. Himuro et al., “BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer,” Gastric Cancer, vol. 19, pp. 827–838, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Zeng, J. Zhu, L. Shan et al., “The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review,” Drug Design, Development and Therapy, vol. 9, pp. 2149–2157, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. Q. Yu, Q. Guo, L. Chen, and S. Liu, “Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review,” Drug Design, Development and Therapy, vol. 9, pp. 2171–2178, 2015. View at Publisher · View at Google Scholar · View at Scopus